A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive,

ID Number 14-0830

Principal Investigator(s)
Amy Tiersten

Department(s) or Division(s)
Hematology and Medical Oncology


This study is evaluating an experimental drug called LEE011.  Experimental means the drug is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of women with breast cancer.  The purpose of this study is to learn whether LEE011 or placebo, when added to standard treatment (letrozole) helps to reduce the growth of breast cancer cells in postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer.  A comparison will be done to learn which of the two study drug regimens (letrozole plus LEE011 or letrozole plus placebo) gives better results.

Contact Information
(212) 824-7309

Recruiting Patients: Yes